Patents Assigned to Suven Life Science Limited
-
Patent number: 9636335Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.Type: GrantFiled: June 10, 2015Date of Patent: May 2, 2017Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kambhampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
-
Patent number: 9540321Abstract: A process suitable for adoption to large scale manufacture of 1-[(2-bromophenyl-sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.Type: GrantFiled: February 20, 2014Date of Patent: January 10, 2017Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Rama Sastri Kambhampati, Anil Karbhari Shinde, Venkateswarlu Jasti
-
Patent number: 9518028Abstract: The present invention relates to process for the preparation of 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid calcium having formula (I). The compound of formula (I) has adopted name “Rosuvastatin Calcium”. The present invention is also related to novel intermediates of formula (4) and formula (5) used in preparation of formula (I), and process of their preparation.Type: GrantFiled: November 18, 2013Date of Patent: December 13, 2016Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Udaya Bhaskara Rao Siripalli, Veera Reddy Arava, Rajendiran Chinnapillai, Anji Reddy Middekadi, Naresh Raju Makaraju, Venkateswarlu Jasti
-
Publication number: 20160311797Abstract: The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxy-tryptamine 4 (5-HT4) receptor agonists.Type: ApplicationFiled: February 24, 2014Publication date: October 27, 2016Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Shankar Reddy GAGGINAPALLY, Venkateswarlu JASTI
-
Publication number: 20160304468Abstract: The present invention relates to process for the preparation of 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid calcium having formula (I). The compound of formula (I) has adopted name “Rosuvastatin Calcium”. The present invention is also related to novel intermediates of formula (4) and formula (5) used in preparation of formula (I), and process of their preparation.Type: ApplicationFiled: November 18, 2013Publication date: October 20, 2016Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Udaya Bhaskara Rao SIRIPALLI, Veera Reddy ARAVA, Rajendiran CHINNAPILLAI, Anji Reddy MIDDEKADI, Naresh Raju MAKARAJU, Venkateswarlu JASTI
-
Publication number: 20160297759Abstract: A process suitable for adoption to large scale manufacture of 1-[(2-bromophenyl-sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.Type: ApplicationFiled: February 20, 2014Publication date: October 13, 2016Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Rama Sastri KAMBHAMPATI, Anil Karbhari SHINDE, Venkateswarlu JASTI
-
Publication number: 20160280694Abstract: The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptor agonists.Type: ApplicationFiled: October 18, 2013Publication date: September 29, 2016Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Venkateswarlu JASTI
-
Publication number: 20160200691Abstract: The present invention provides a process for the large scale production of 1H-[1,2,3]triazole of formula (I) and its intermediate 1-benzyl-1H-[1,2,3]triazole of formula (II) by using benzyl azide and vinyl acetate as starting materials. This process is economical, environment friendly and safer by avoiding use of special equipment.Type: ApplicationFiled: January 27, 2014Publication date: July 14, 2016Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Veera Reddy Arava, Sashibhushan Malreddy, Chalapathi Lagupudi, Venkateswarlu Jasti
-
Patent number: 9328092Abstract: The present invention relates to novel acrylamide compounds of formula (I): wherein A, X, R1, and Y are as defined herein, and their pharmaceutically acceptable salts and process of their preparation. The compounds of formula (I) are useful in the treatment of various disorders that related to Histamine H3 receptors.Type: GrantFiled: December 5, 2012Date of Patent: May 3, 2016Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Adi Reddy Dwarampudi, Venkateswarlu Jasti
-
Patent number: 9079888Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above compounds of formula (I), and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors.Type: GrantFiled: June 7, 2011Date of Patent: July 14, 2015Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Ramasastri Kambhampati, Amol Dinakar Deshpande, Adi Reddy Dwarampudi, Narasimhareddy Gangadasari, Sangram Keshari Saraf, Vishwottam Nagaraj Kandikere, Pradeep Jayarajan, Ishtiyaque Ahmad, Mohmadsadik Abdulhamid Mulla, Venkateswarlu Jasti
-
Patent number: 9018231Abstract: The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment/prevention of various disorders that are related to 5-HT6 receptor functions.Type: GrantFiled: March 24, 2010Date of Patent: April 28, 2015Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Rajesh Kumar Badange, Veena Reballi, Anil Kashinath Chindhe, Rambabu Namala, Mohamad Sadik Abdulhamid Mulla, Ishtiyaque Ahmad, Renny Abraham, Venkateswarlu Jasti
-
Patent number: 8912179Abstract: The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors, for example cognitive disorders, sleep disorders, obesity and pain.Type: GrantFiled: November 15, 2010Date of Patent: December 16, 2014Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Ramasastri Kambhampati, Rambabu Namala, Adi Reddy Dwarampudi, Laxman Kota, Murlimohan Gampa, Padmavathi Kodru, Taraka Naga Vinaykumar Tiriveedhi, Vishwottam Nagaraj Kandikere, Nageshwara Rao Muddana, Ramanatha Shrikantha Saralaya, Pradeep Jayarajan, Dhanalakshmi Shanmuganathan, Ishtiyaque Ahmad, Venkateswarlu Jasti
-
Publication number: 20140187581Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.Type: ApplicationFiled: January 5, 2012Publication date: July 3, 2014Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kamphampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
-
Publication number: 20140148440Abstract: The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors, for example cognitive disorders, sleep disorders, obesity and pain.Type: ApplicationFiled: November 15, 2010Publication date: May 29, 2014Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Ramasastri Kambhampati, Rambabu Namala, Adi Reddy Dwarampudi, Laxman Kota, Murlimohan Gampa, Padmavathi Kodru, Taraka Naga Vinaykumar Tiriveedhi, Vishwottam Nagaraj Kandikere, Nageshwara Rao Muddana, Ramanatha Shrikantha Saralaya, Pradeep Jayarajan, Dhanalakshmi Shanmuganathan, Ishtiyaque Ahmad, Venkateswarlu Jasti
-
Patent number: 8735423Abstract: The present invention relates to novel bicyclic compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment and prevention of various disorders that are related to ?4?2 nicotinic receptors.Type: GrantFiled: December 31, 2009Date of Patent: May 27, 2014Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Srinivas Veeramalla, Srinivasa Rao Ravella, Ishtiyaque Ahmad, Pradeep Jayarajan, Anil Karbhari Shinde, Rama Sastri Kambhampti, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20140135304Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors.Type: ApplicationFiled: June 7, 2011Publication date: May 15, 2014Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Ramasastri Kambhampati, Amol Dinakar Deshpande, Adi Reddy Dwarampudi, Narasimhareddy Gangadasari, Sangram Keshari Saraf, Vishwottam Nagaraj Kandikere, Pradeep Jayarajan, Ishtiyaque Ahmad, Mohmadsadik Abdulhamid Mulla, Venkateswarlu Jasti
-
Patent number: 8653071Abstract: The present invention relates to novel ?4?2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel ?4?2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.Type: GrantFiled: May 3, 2010Date of Patent: February 18, 2014Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Kana Ram Kumawat, Ishtiyaque Ahmad, Pradeep Jayarajan, Anil Karbhari Shinde, Nagaraj Vishwottam Kandikere, Koteshwara Mudigonda, Venkateswarlu Jasti
-
Patent number: 8598204Abstract: The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.Type: GrantFiled: December 29, 2009Date of Patent: December 3, 2013Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Ishtiyaque Ahmad, Pradeep Jayarajan, Nagaraj Vishwottam Kandikere, Anil Karbhari Shinde, Rama Sastri Kambhampati, Gopinadh Bhyrapuneni, Jyothsna Ravula, Sriramachandra Murthy Patnala, Venkateswarlu Jasti
-
Patent number: 8551718Abstract: The present invention provides novel functional assay for 5-HT2A, histamine H1 or adrenergic alpha 1b receptors, by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set. The novel assay of the invention is useful in identification of compounds acting through 5-HT2A, histamine H1 or adrenergic alpha 1b receptors. Furthermore, the assay offers utility in categorizing compounds in to agonist, partial agonist, inverse agonist and antagonist classes. The novel assay can be scaled up to any high throughput format.Type: GrantFiled: March 31, 2010Date of Patent: October 8, 2013Assignee: Suven Life Science LimitedInventors: Ishtiyaque Ahmad, Reddy Venkat Mekala, Reddy Muddukrishna Chillakur, Ramkumar Subramaniam, Jyothsna Ravula, Sriramachandra Murthy Patnala, Ramakrishna Nirogi, Venkateswarlu Jasti
-
Patent number: 8470830Abstract: Compounds including 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them and a process for the preparation of these compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.Type: GrantFiled: July 26, 2007Date of Patent: June 25, 2013Assignee: Suven Life Sciences LimitedInventors: Venkata Satya Nirogi Ramakrishna, Rama Sastri Kambhampati, Jagadishbabu Konda, Prabhakar Kothmirkar, Venkateswarlu Jasti